Dr. Sandy Eldridge is a Senior Principal Scientist in the Toxicology and Pharmacology Branch of the Developmental Therapeutics
Program at the National Cancer Institute (NCI) where she has spent the past 10 years contributing to the drug development efforts of the
Division of Cancer Treatment and Diagnosis. Dr. Eldridge serves as a toxicologist on project teams and leads the scientific efforts of the
Laboratory of Investigative Toxicology to support mechanistic understanding of compound- or target-mediated toxicities in discovery and
development of cancer therapeutics.
Dr. Eldridge is a long-standing member of the American College of Toxicology, Society of Toxicology (SOT), and Society of Toxicologic Pathology (STP) and has served in several leadership positions. She currently serves on the Board of Publications for the SOT, editorial board for the ACT’s International Journal of Toxicology, American Board of Toxicology Practice Analysis Task Force and several
committees of the Health and Environmental Sciences Institute (HESI) in a scientific advisory role. Her publication record spans in vitro and in vivo mechanistic toxicology investigations.
Dr. Eldridge is a Fellow in the Academy of Toxicological Sciences, Diplomate of the American Board of Toxicology, and Fellow in the International Academy of Toxicologic Pathology. Prior to joining the NCI, she spent 20 years in preclinical toxicology contract research in various science-based expert and leadership positions. Sandy holds a PhD in Toxicology from the University of Wisconsin-Madison. She completed postdoctoral training at The Hamner Institutes for Health Sciences (previously known as the Chemical Industry Institute of